{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:45:22Z","timestamp":1785800722428,"version":"3.56.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473459"],"award-info":[{"award-number":["82473459"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Liu Liang Expert Workstation of Yunnan Province","award":["202305AF150148"],"award-info":[{"award-number":["202305AF150148"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08354-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:50:53Z","timestamp":1780069853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological and molecular determinants of pancreatic neuroendocrine tumors: toward precision risk stratification"],"prefix":"10.1186","volume":"24","author":[{"given":"Kai Xuan","family":"Cheong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Zhen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-8098","authenticated-orcid":false,"given":"Wen-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"8354_CR1","doi-asserted-by":"publisher","unstructured":"Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic neuroendocrine tumors: molecular mechanisms and therapeutic targets. Cancers (Basel). 2021;13(20). https:\/\/doi.org\/10.3390\/cancers13205117.","DOI":"10.3390\/cancers13205117"},{"issue":"12","key":"8354_CR2","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1016\/j.asjsur.2022.01.094","volume":"45","author":"BS Shyr","year":"2022","unstructured":"Shyr BS, Shyr BU, Chen SC, Shyr YM, Wang SE. Impact of tumor grade on pancreatic neuroendocrine tumors. Asian J Surg. 2022;45(12):2659\u201363. https:\/\/doi.org\/10.1016\/j.asjsur.2022.01.094.","journal-title":"Asian J Surg"},{"key":"8354_CR3","doi-asserted-by":"publisher","unstructured":"Maluchenko A, Maksimov D, Antysheva Z, Krupinova J, Avsievich E, Glazova O, Bodunova N, Karnaukhov N, Feidorov I, Salimgereeva D, Voloshin M, Volchkov P. molecular basis of pancreatic neuroendocrine tumors. Int J Mol Sci. 2024;25(20). https:\/\/doi.org\/10.3390\/ijms252011017.","DOI":"10.3390\/ijms252011017"},{"issue":"10","key":"8354_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"issue":"4","key":"8354_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397. https:\/\/doi.org\/10.1002\/cncr.29099.","journal-title":"Cancer"},{"issue":"4","key":"8354_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3322\/caac.21840","volume":"74","author":"A Chauhan","year":"2024","unstructured":"Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O\u2019Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Shi C. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024;74(4):359\u201367. https:\/\/doi.org\/10.3322\/caac.21840.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8354_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115\u201354. https:\/\/doi.org\/10.1007\/s12022-022-09708-2.","journal-title":"Endocr Pathol"},{"issue":"2","key":"8354_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2214\/ajr.17.18417","volume":"210","author":"R Canellas","year":"2018","unstructured":"Canellas R, Burk KS, Parakh A, Sahani DV. Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. AJR Am J Roentgenol. 2018;210(2):341\u20136. https:\/\/doi.org\/10.2214\/ajr.17.18417.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"8354_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.5858\/arpa.2019-0654-RA","volume":"144","author":"LH Tang","year":"2020","unstructured":"Tang LH. Pancreatic Neuroendocrine Neoplasms: Landscape and Horizon. Arch Pathol Lab Med. 2020;144(7):816\u201328. https:\/\/doi.org\/10.5858\/arpa.2019-0654-RA.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"8354_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jamcollsurg.2014.01.001","volume":"218","author":"E Dogeas","year":"2014","unstructured":"Dogeas E, Karagkounis G, Heaphy CM, Hirose K, Pawlik TM, Wolfgang CL, Meeker A, Hruban RH, Cameron JL, Choti MA. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases. J Am Coll Surg. 2014;218(4):628\u201335. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2014.01.001.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"8354_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00428-021-03202-6","volume":"480","author":"A Kasajima","year":"2022","unstructured":"Kasajima A, Konukiewitz B, Schlitter AM, Weichert W, Kl\u00f6ppel G. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Arch. 2022;480(2):359\u201368. https:\/\/doi.org\/10.1007\/s00428-021-03202-6.","journal-title":"Virchows Arch"},{"issue":"8","key":"8354_CR12","doi-asserted-by":"publisher","first-page":"e13318","DOI":"10.1111\/jne.13318","volume":"35","author":"J Hofland","year":"2023","unstructured":"Hofland J, Falconi M, Christ E, Casta\u00f1o JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. https:\/\/doi.org\/10.1111\/jne.13318.","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"8354_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3892\/ijo.2016.3826","volume":"50","author":"G Yang","year":"2017","unstructured":"Yang G, Ji M, Chen J, Chen R, Chen Y, Fu D, Hou B, Huang H, Jiang L, Jin K, Ke N, Li Y, Li Y, Liang H, Liu A, Luo J, Ni Q, Shao C, Shen B, Shao C. Surgery management for sporadic small (\u2264\u20092\u00a0cm), non-functioning pancreatic neuroendocrine tumors: a consensus statement by the Chinese Study Group for Neuroendocrine Tumors (CSNET). Int J Oncol. 2017;50(2):567\u201374. https:\/\/doi.org\/10.3892\/ijo.2016.3826.","journal-title":"Int J Oncol"},{"issue":"1","key":"8354_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bpg.2007.10.008","volume":"22","author":"N Alexakis","year":"2008","unstructured":"Alexakis N, Neoptolemos JP. Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2008;22(1):183\u2013205. https:\/\/doi.org\/10.1016\/j.bpg.2007.10.008.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"Suppl 1","key":"8354_CR15","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1016\/j.ijsu.2015.12.052","volume":"28","author":"M Orditura","year":"2016","unstructured":"Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F. Pancreatic neuroendocrine tumors: Nosography, management and treatment. Int J Surg. 2016;28(Suppl 1):S156\u201362. https:\/\/doi.org\/10.1016\/j.ijsu.2015.12.052.","journal-title":"Int J Surg"},{"issue":"1","key":"8354_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.clcc.2022.12.002","volume":"22","author":"VT Chang","year":"2023","unstructured":"Chang VT, Sandifer C, Zhong F. GI Symptoms in Pancreatic Cancer. Clin Colorectal Cancer. 2023;22(1):24\u201333. https:\/\/doi.org\/10.1016\/j.clcc.2022.12.002.","journal-title":"Clin Colorectal Cancer"},{"key":"8354_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2017.10.036","volume":"412","author":"H Gao","year":"2018","unstructured":"Gao H, Liu L, Wang W, Xu H, Jin K, Wu C, Qi Z, Zhang S, Liu C, Xu J, Ni Q, Yu X. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. Cancer Lett. 2018;412:188\u201393. https:\/\/doi.org\/10.1016\/j.canlet.2017.10.036.","journal-title":"Cancer Lett"},{"issue":"3","key":"8354_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.pan.2019.02.011","volume":"19","author":"H Gao","year":"2019","unstructured":"Gao H, Wang W, Xu H, Wu C, Jin W, Zhang S, Xu J, Ni Q, Yu X, Liu L. Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. Pancreatology. 2019;19(3):472\u20137. https:\/\/doi.org\/10.1016\/j.pan.2019.02.011.","journal-title":"Pancreatology"},{"issue":"47","key":"8354_CR19","doi-asserted-by":"publisher","first-page":"82784","DOI":"10.18632\/oncotarget.20007","volume":"8","author":"M Yang","year":"2017","unstructured":"Yang M, Ke NW, Zhang Y, Tan CL, Tian BL, Liu XB, Huang W, Nunes Q, Sutton R. Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system? Oncotarget. 2017;8(47):82784\u201395. https:\/\/doi.org\/10.18632\/oncotarget.20007.","journal-title":"Oncotarget"},{"key":"8354_CR20","doi-asserted-by":"publisher","first-page":"1123642","DOI":"10.3389\/fendo.2023.1123642","volume":"14","author":"S Luo","year":"2023","unstructured":"Luo S, Wang J, Wu L, Wang C, Yang J, Li M, Zhang L, Ge J, Sun C, Li E, Lei J, Liao Y, Zhou F, Liao W. Epidemiological trends for functional pancreatic neuroendocrine tumors: A study combining multiple imputation with age adjustment. Front Endocrinol (Lausanne). 2023;14:1123642. https:\/\/doi.org\/10.3389\/fendo.2023.1123642.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"8354_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/mpa.0000000000000718","volume":"46","author":"R Yu","year":"2017","unstructured":"Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, Fan X. A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. Pancreas. 2017;46(1):48\u201356. https:\/\/doi.org\/10.1097\/mpa.0000000000000718.","journal-title":"Pancreas"},{"issue":"6","key":"8354_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/ejendo\/lvad157","volume":"189","author":"M Perrier","year":"2023","unstructured":"Perrier M, Brugel M, G\u00e9rard L, Goichot B, Li\u00e8vre A, Lepage C, Hautefeuille V, Cao D, Smith C, Thuillier D, Cros P, Cadiot J, Walter G, T., de Mestier L. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network. Eur J Endocrinol. 2023;189(6):575\u201383. https:\/\/doi.org\/10.1093\/ejendo\/lvad157.","journal-title":"Eur J Endocrinol"},{"key":"8354_CR23","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1038\/ncomms3810","volume":"4","author":"Y Cao","year":"2013","unstructured":"Cao Y, Gao Z, Li L, Jiang X, Shan A, Cai J, Peng Y, Li Y, Jiang X, Huang X, Wang J, Wei Q, Qin G, Zhao J, Jin X, Liu L, Li Y, Wang W, Wang J, Ning G. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun. 2013;4:2810. https:\/\/doi.org\/10.1038\/ncomms3810.","journal-title":"Nat Commun"},{"issue":"9","key":"8354_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.eprac.2021.02.016","volume":"27","author":"YL Song","year":"2021","unstructured":"Song YL, Xu J, Zhao DC, Zhang TP, Jin KZ, Zhu LM, Yu S, Chen YJ. Mutation and Expression of Gene YY1 in Pancreatic Neuroendocrine Tumors and Its Clinical Significance. Endocr Pract. 2021;27(9):874\u201380. https:\/\/doi.org\/10.1016\/j.eprac.2021.02.016.","journal-title":"Endocr Pract"},{"issue":"5","key":"8354_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1136\/gutjnl-2018-317233","volume":"69","author":"X Hong","year":"2020","unstructured":"Hong X, Qiao S, Li F, Wang W, Jiang R, Wu H, Chen H, Liu L, Peng J, Wang J, Jia C, Liang X, Dai H, Jiang J, Zhang T, Liao Q, Dai M, Cong L, Han X, Wu W. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system. Gut. 2020;69(5):877\u201387. https:\/\/doi.org\/10.1136\/gutjnl-2018-317233.","journal-title":"Gut"},{"issue":"12","key":"8354_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3748\/wjg.v30.i12.1670","volume":"30","author":"S Giri","year":"2024","unstructured":"Giri S, Sahoo J. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope. World J Gastroenterol. 2024;30(12):1670\u20135. https:\/\/doi.org\/10.3748\/wjg.v30.i12.1670.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"8354_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11864-023-01085-0","volume":"24","author":"L Magi","year":"2023","unstructured":"Magi L, Marasco M, Rinzivillo M, Faggiano A, Panzuto F. Management of Functional Pancreatic Neuroendocrine Neoplasms. Curr Treat Options Oncol. 2023;24(7):725\u201341. https:\/\/doi.org\/10.1007\/s11864-023-01085-0.","journal-title":"Curr Treat Options Oncol"},{"key":"8354_CR28","doi-asserted-by":"publisher","first-page":"102803","DOI":"10.1016\/j.ctrv.2024.102803","volume":"129","author":"F Panzuto","year":"2024","unstructured":"Panzuto F, Lamarca A, Fazio N. Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors. Cancer Treat Rev. 2024;129:102803. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102803.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"8354_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12885-020-07356-5","volume":"20","author":"M Yang","year":"2020","unstructured":"Yang M, Zeng L, Ke NW, Tan CL, Tian BL, Liu XB, Xiang B, Zhang Y. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. BMC Cancer. 2020;20(1):906. https:\/\/doi.org\/10.1186\/s12885-020-07356-5.","journal-title":"BMC Cancer"},{"issue":"10","key":"8354_CR30","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S, Ohike N, Saka B, Sokmensuer C, Leblebici CB, Xue Y, Reid MD, Krasinskas AM, Kooby D, Maithel SK, Sarmiento J, Cheng JD, Taskin OC, Kapran Y, Tarcan ZC, Luchini C, Scarpa A, Adsay NV. Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to <\u200910%) Versus 2B (10% to \u2264\u200920%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols. Ann Surg Oncol. 2024;31(10):7001\u201311. https:\/\/doi.org\/10.1245\/s10434-024-15632-y.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"8354_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12022-025-09866-z","volume":"36","author":"AL Kiemen","year":"2025","unstructured":"Kiemen AL, Young ED, Blackford AL, Wu P, Burkhart RA, Burns WR, Cameron JL, Lafaro K, Shubert C, Gaillard Z, Ebong UA, Reucroft I, Shen Y, Dequiedt L, Matos V, Kl\u00f6ppel G, Kasajima A, He J, Hruban RH. Prognostic Features in Surgically Resected Well-Differentiated Pancreatic Neuroendocrine Tumors: an Analysis of 904 Patients with 7882 Person-Years of Follow-Up. Endocr Pathol. 2025;36(1):24. https:\/\/doi.org\/10.1007\/s12022-025-09866-z.","journal-title":"Endocr Pathol"},{"issue":"9","key":"8354_CR32","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/pas.0000000000000662","volume":"40","author":"LH Tang","year":"2016","unstructured":"Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40(9):1192\u2013202. https:\/\/doi.org\/10.1097\/pas.0000000000000662.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"8354_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/jcoop.20.00010","volume":"16","author":"D Li","year":"2020","unstructured":"Li D, Rock A, Kessler J, Ballena R, Hyder S, Mo C, Chang S, Singh G. Understanding the Management and Treatment of Well-Differentiated Pancreatic Neuroendocrine Tumors: A Clinician\u2019s Guide to a Complex Illness. JCO Oncol Pract. 2020;16(11):720\u20138. https:\/\/doi.org\/10.1200\/jcoop.20.00010.","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"8354_CR34","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.cgh.2024.03.029","volume":"22","author":"S Hijioka","year":"2024","unstructured":"Hijioka S, Yamashige D, Esaki M, Honda G, Higuchi R, Masui T, Shimizu Y, Ohtsuka M, Kumamoto Y, Katanuma A, Gotohda N, Akita H, Unno M, Endo I, Yokoyama Y, Yamada S, Matsumoto I, Ohtsuka T, Hirano S, Satoi S. Factors Affecting Nonfunctioning Small Pancreatic Neuroendocrine Neoplasms and Proposed New Treatment Strategies. Clin Gastroenterol Hepatol. 2024;22(7):1416\u2013e14265. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.029.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"8354_CR35","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1530\/ec-17-0293","volume":"6","author":"L Mills","year":"2017","unstructured":"Mills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A, Srinivasan P, Menon K, Cotoi C, Khan S, Cave J, Armstrong T, Weickert MO, Izbicki J, Schrader J, Frilling A, Ramage JK, Srirajaskanthan R. Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours. Endocr Connect. 2017;6(8):876\u201385. https:\/\/doi.org\/10.1530\/ec-17-0293.","journal-title":"Endocr Connect"},{"issue":"9","key":"8354_CR36","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1245\/s10434-014-3701-y","volume":"21","author":"Y Kishi","year":"2014","unstructured":"Kishi Y, Shimada K, Nara S, Esaki M, Hiraoka N, Kosuge T. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size. Ann Surg Oncol. 2014;21(9):2882\u20138. https:\/\/doi.org\/10.1245\/s10434-014-3701-y.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"8354_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.surg.2012.08.038","volume":"152","author":"LC Lee","year":"2012","unstructured":"Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, Levy MJ, Huebner M. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152(6):965\u201374. https:\/\/doi.org\/10.1016\/j.surg.2012.08.038.","journal-title":"Surgery"},{"issue":"8","key":"8354_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/bjs\/znab088","volume":"108","author":"CM Heidsma","year":"2021","unstructured":"Heidsma CM, Engelsman AF, van Dieren S, Stommel MWJ, de Hingh I, Vriens M, Hol L, Festen S, Mekenkamp L, Hoogwater FJH, Daams F, Kl\u00fcmpen HJ, Besselink MG, van Eijck CH, van Nieveen EJ. Watchful waiting for small non-functional pancreatic neuroendocrine tumours: nationwide prospective cohort study (PANDORA). Br J Surg. 2021;108(8):888\u201391. https:\/\/doi.org\/10.1093\/bjs\/znab088.","journal-title":"Br J Surg"},{"key":"8354_CR39","doi-asserted-by":"publisher","first-page":"598438","DOI":"10.3389\/fmed.2020.598438","volume":"7","author":"S Partelli","year":"2020","unstructured":"Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P, Panzuto F, Landoni L, Tomazic A, Ibrahim T, Kaltsas G, Bertani E, Sauvanet A, Segelov E, Caplin M, Coppa J, Armstrong T, Weickert MO, Butturini G, Falconi M. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN)\u2009\u2264\u20092\u00a0cm: Study Protocol for a Prospective Observational Study. Front Med (Lausanne). 2020;7:598438. https:\/\/doi.org\/10.3389\/fmed.2020.598438.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"8354_CR40","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1245\/s10434-023-13193-0","volume":"30","author":"Y Nanno","year":"2023","unstructured":"Nanno Y, Toyama H, Matsumoto I, Uemura J, Asari S, Goto T, Lee D, Murakami T, Komatsu S, Yanagimoto H, Kido M, Ajiki T, Okano K, Takeyama Y, Fukumoto T. Reappraisal of Malignant Risk Assessment for Small (\u2264\u200920\u00a0mm) Non-functioning Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2023;30(6):3493\u2013500. https:\/\/doi.org\/10.1245\/s10434-023-13193-0.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"8354_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jso.26931","volume":"126","author":"D Arra","year":"2022","unstructured":"Arra D, Ribeiro HSC, Henklain G, Barbosa A, Torres SM, Diniz AL, Godoy AL, Farias IC, Costa WL Jr., Coimbra FJF. Surgery or active surveillance for pNETs\u2009<\u20092\u00a0cm: Preliminary results from a single center Brazilian cohort. J Surg Oncol. 2022;126(1):168\u201374. https:\/\/doi.org\/10.1002\/jso.26931.","journal-title":"J Surg Oncol"},{"issue":"3","key":"8354_CR42","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.surg.2022.04.013","volume":"172","author":"J Perinel","year":"2022","unstructured":"Perinel J, Nappo G, Zerbi A, Heidsma CM, van Dijkum N, Han EJM, Yoon HS, Satoi YS, Demir S, Friess IE, Vashist H, Izbicki Y, Muller J, Gloor AC, Sandini B, Gianotti M, Subtil L, F., Adham M. Sporadic nonfunctional pancreatic neuroendocrine tumors: Risk of lymph node metastases and aggressiveness according to tumor size: A multicenter international study. Surgery. 2022;172(3):975\u201381. https:\/\/doi.org\/10.1016\/j.surg.2022.04.013.","journal-title":"Surgery"},{"issue":"6","key":"8354_CR43","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.surg.2022.08.022","volume":"172","author":"AA Javed","year":"2022","unstructured":"Javed AA, Pulvirenti A, Zheng J, Michelakos T, Sekigami Y, Razi S, McIntyre CA, Thompson E, Klimstra DS, Deshpande V, Singhi AD, Weiss MJ, Wolfgang CL, Cameron JL, Wei AC, Zureikat AH, Ferrone CR, He J. A novel tool to predict nodal metastasis in small pancreatic neuroendocrine tumors: A multicenter study. Surgery. 2022;172(6):1800\u20136. https:\/\/doi.org\/10.1016\/j.surg.2022.08.022.","journal-title":"Surgery"},{"issue":"3","key":"8354_CR44","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.hpb.2017.08.034","volume":"20","author":"VJ Sallinen","year":"2018","unstructured":"Sallinen VJ, Large L, Tieftrunk TYS, Galeev E, Kovalenko S, Haugvik Z, Antila SP, Franklin A, Martinez-Moneo O, Robinson E, Panzuto SM, Regenet F, Muffatti N, Partelli F, Wiese S, Ruszniewski D, Dousset P, Edwin B, Bartsch B, Gaujoux DK, S. Prognosis of sporadic resected small (\u2264\u20092\u00a0cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. HPB (Oxford). 2018;20(3):251\u20139. https:\/\/doi.org\/10.1016\/j.hpb.2017.08.034.","journal-title":"HPB (Oxford)"},{"key":"8354_CR45","doi-asserted-by":"publisher","first-page":"907415","DOI":"10.3389\/fendo.2022.907415","volume":"13","author":"Q Tan","year":"2022","unstructured":"Tan Q, Wang X, Li Y, Liu Y, Liu X, Ke N. Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study. Front Endocrinol (Lausanne). 2022;13:907415. https:\/\/doi.org\/10.3389\/fendo.2022.907415.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"8354_CR46","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00428-018-2407-0","volume":"473","author":"JH Kwon","year":"2018","unstructured":"Kwon JH, Kim HJ, Park DH, Lee YJ, Heaphy CM, Kl\u00f6ppel G, Hruban RH, Hong SM. Incidentally detected pancreatic neuroendocrine microadenoma with lymph node metastasis. Virchows Arch. 2018;473(5):649\u201353. https:\/\/doi.org\/10.1007\/s00428-018-2407-0.","journal-title":"Virchows Arch"},{"issue":"3","key":"8354_CR47","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1245\/s10434-020-08850-7","volume":"28","author":"M Tanaka","year":"2021","unstructured":"Tanaka M, Heckler M, Mihaljevic AL, Probst P, Klaiber U, Heger U, Schimmack S, B\u00fcchler MW, Hackert T. Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2021;28(3):1614\u201324. https:\/\/doi.org\/10.1245\/s10434-020-08850-7.","journal-title":"Ann Surg Oncol"},{"key":"8354_CR48","doi-asserted-by":"publisher","first-page":"1140873","DOI":"10.3389\/fendo.2023.1140873","volume":"14","author":"W Mei","year":"2023","unstructured":"Mei W, Cao F, Lu J, Qu C, Fang Z, Li J, Li F. Characteristics of small pancreatic neuroendocrine tumors and risk factors for invasion and metastasis. Front Endocrinol (Lausanne). 2023;14:1140873. https:\/\/doi.org\/10.3389\/fendo.2023.1140873.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"8354_CR49","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.pan.2017.08.003","volume":"17","author":"T Mizumoto","year":"2017","unstructured":"Mizumoto T, Toyama H, Terai S, Mukubou H, Yamashita H, Shirakawa S, Nanno Y, Sofue K, Kido M, Ajiki T, Fukumoto T. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology. 2017;17(6):956\u201361. https:\/\/doi.org\/10.1016\/j.pan.2017.08.003.","journal-title":"Pancreatology"},{"issue":"1","key":"8354_CR50","doi-asserted-by":"publisher","first-page":"2528340","DOI":"10.1080\/08941939.2025.2528340","volume":"38","author":"H Hu","year":"2025","unstructured":"Hu H, Chen C, Zheng Z, Meng F, Zhang S, Li P. Prognostic Factors and Management Approaches for Small Nonfunctional Pancreatic Neuroendocrine Tumors: Insights from SEER Data. J Invest Surg. 2025;38(1):2528340. https:\/\/doi.org\/10.1080\/08941939.2025.2528340.","journal-title":"J Invest Surg"},{"issue":"10","key":"8354_CR51","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3748\/wjg.v28.i10.1009","volume":"28","author":"JM Fang","year":"2022","unstructured":"Fang JM, Li J, Shi J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol. 2022;28(10):1009\u201323. https:\/\/doi.org\/10.3748\/wjg.v28.i10.1009.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"8354_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000357035","volume":"58","author":"S Chen","year":"2014","unstructured":"Chen S, Wang X, Lin J. Fine needle aspiration of oncocytic variants of pancreatic neuroendocrine tumor: a report of three misdiagnosed cases. Acta Cytol. 2014;58(2):131\u20137. https:\/\/doi.org\/10.1159\/000357035.","journal-title":"Acta Cytol"},{"issue":"2","key":"8354_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/01.pas.0000184819.71752.ad","volume":"30","author":"R Singh","year":"2006","unstructured":"Singh R, Basturk O, Klimstra DS, Zamboni G, Chetty R, Hussain S, La Rosa S, Yilmaz A, Capelli P, Capella C, Cheng JD, Adsay NV. Lipid-rich variant of pancreatic endocrine neoplasms. Am J Surg Pathol. 2006;30(2):194\u2013200. https:\/\/doi.org\/10.1097\/01.pas.0000184819.71752.ad.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"8354_CR54","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/01.pas.0000164370.81132.25","volume":"29","author":"SY Zee","year":"2005","unstructured":"Zee SY, Hochwald SN, Conlon KC, Brennan MF, Klimstra DS. Pleomorphic pancreatic endocrine neoplasms: a variant commonly confused with adenocarcinoma. Am J Surg Pathol. 2005;29(9):1194\u2013200. https:\/\/doi.org\/10.1097\/01.pas.0000164370.81132.25.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"8354_CR55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00000478-200402000-00018","volume":"28","author":"J Shia","year":"2004","unstructured":"Shia J, Erlandson RA, Klimstra DS. Whorls of intermediate filaments with entrapped neurosecretory granules correspond to the rhabdoid inclusions seen in pancreatic endocrine neoplasms. Am J Surg Pathol. 2004;28(2):271\u20133. https:\/\/doi.org\/10.1097\/00000478-200402000-00018.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"8354_CR56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12022-020-09628-z","volume":"31","author":"Y Xue","year":"2020","unstructured":"Xue Y, Reid MD, Pehlivanoglu B, Obeng RC, Jiang H, Memis B, Lui SK, Sarmiento J, Kooby D, Maithel SK, El-Rayes B, Basturk O, Adsay V. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. Endocr Pathol. 2020;31(3):239\u201353. https:\/\/doi.org\/10.1007\/s12022-020-09628-z.","journal-title":"Endocr Pathol"},{"issue":"4","key":"8354_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","volume":"35","author":"NM Joseph","year":"2024","unstructured":"Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocr Pathol. 2024;35(4):325\u201337. https:\/\/doi.org\/10.1007\/s12022-024-09835-y.","journal-title":"Endocr Pathol"},{"issue":"6","key":"8354_CR58","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/01.pas.0000112546.57641.c7","volume":"28","author":"S van Eeden","year":"2004","unstructured":"van Eeden S, de Leng WW, Offerhaus GJ, Morsink FH, Weterman MA, de Krijger RR, Kl\u00f6ppel G, Klimstra DS. Ductuloinsular tumors of the pancreas: endocrine tumors with entrapped nonneoplastic ductules. Am J Surg Pathol. 2004;28(6):813\u201320. https:\/\/doi.org\/10.1097\/01.pas.0000112546.57641.c7.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"8354_CR59","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cncy.21982","volume":"126","author":"CS Sigel","year":"2018","unstructured":"Sigel CS, Silva K, Reid VW, Chhieng MD, Basturk D, Sigel O, Daniel KM, Klimstra TD, D. S., Tang LH. Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study. Cancer Cytopathol. 2018;126(5):326\u201335. https:\/\/doi.org\/10.1002\/cncy.21982.","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"8354_CR60","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1078-0432.Ccr-15-0548","volume":"22","author":"LH Tang","year":"2016","unstructured":"Tang LH, Untch BR, Reidy DL, O\u2019Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016;22(4):1011\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0548.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8354_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cncy.21934","volume":"126","author":"CS Sigel","year":"2018","unstructured":"Sigel CS, Silva K, Reid VW, Chhieng MD, Basturk D, Sigel O, Daniel KM, Klimstra TD, D. S., Tang LH. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study. Cancer Cytopathol. 2018;126(1):44\u201353. https:\/\/doi.org\/10.1002\/cncy.21934.","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"8354_CR62","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00268-009-0290-1","volume":"34","author":"P Goudet","year":"2010","unstructured":"Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, M\u00e9n\u00e9gaux F, Chabrier G, Borson-Chazot F, Tabarin A, Bouchard P, Delemer B, Beckers A, Bonithon-Kopp C. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d\u2019Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249\u201355. https:\/\/doi.org\/10.1007\/s00268-009-0290-1.","journal-title":"World J Surg"},{"key":"8354_CR63","doi-asserted-by":"publisher","first-page":"681013","DOI":"10.3389\/fendo.2021.681013","volume":"12","author":"P Soczomski","year":"2021","unstructured":"Soczomski P, Jurecka-Lubieniecka B, Krzywon A, Cortez AJ, Zgliczynski S, Rogozik N, Oczko-Wojciechowska M, Pawlaczek A, Bednarczuk T, Jarzab B. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations. Front Endocrinol (Lausanne). 2021;12:681013. https:\/\/doi.org\/10.3389\/fendo.2021.681013.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8354_CR64","doi-asserted-by":"publisher","unstructured":"Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr., Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199\u2009\u2013\u2009203. https:\/\/doi.org\/10.1126\/science.1200609.","DOI":"10.1126\/science.1200609"},{"issue":"8","key":"8354_CR65","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1053\/j.gastro.2018.02.026","volume":"154","author":"S Roy","year":"2018","unstructured":"Roy S, LaFramboise WA, Liu TC, Cao D, Luvison A, Miller C, Lyons MA, O\u2019Sullivan RJ, Zureikat AH, Hogg ME, Tsung A, Lee KK, Bahary N, Brand RE, Chennat JS, Fasanella KE, McGrath K, Nikiforova MN, Papachristou GI, Singhi AD. Loss of Chromatin-Remodeling Proteins and\/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology. 2018;154(8):2060\u2013e20638. https:\/\/doi.org\/10.1053\/j.gastro.2018.02.026.","journal-title":"Gastroenterology"},{"key":"8354_CR66","doi-asserted-by":"publisher","first-page":"591501","DOI":"10.3389\/fendo.2020.591501","volume":"11","author":"C Mele","year":"2020","unstructured":"Mele C, Mencarelli M, Caputo M, Mai S, Pagano L, Aimaretti G, Scacchi M, Falchetti A, Marzullo P. Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. Front Endocrinol (Lausanne). 2020;11:591501. https:\/\/doi.org\/10.3389\/fendo.2020.591501.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8354_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41525-018-0058-3","volume":"3","author":"B Lawrence","year":"2018","unstructured":"Lawrence B, Blenkiron C, Parker K, Tsai P, Fitzgerald S, Shields P, Robb T, Yeong ML, Kramer N, James S, Black M, Fan V, Poonawala N, Yap P, Coats E, Woodhouse B, Ramsaroop R, Yozu M, Robinson B, Print C. Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. NPJ Genom Med. 2018;3:18. https:\/\/doi.org\/10.1038\/s41525-018-0058-3.","journal-title":"NPJ Genom Med"},{"issue":"1","key":"8354_CR68","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-018-1566-8","volume":"62","author":"F Marini","year":"2018","unstructured":"Marini F, Giusti F, Fossi C, Cioppi F, Cianferotti L, Masi L, Boaretto F, Zovato S, Cetani F, Colao A, Dav\u00ec MV, Faggiano A, Fanciulli G, Ferolla P, Ferone D, Loli P, Mantero F, Marcocci C, Opocher G, Brandi ML. Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine. 2018;62(1):215\u201333. https:\/\/doi.org\/10.1007\/s12020-018-1566-8.","journal-title":"Endocrine"},{"issue":"5","key":"8354_CR69","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/gut.2006.108910","volume":"56","author":"M Anlauf","year":"2007","unstructured":"Anlauf M, Perren A, Henopp T, Rudolf T, Garbrecht N, Schmitt A, Raffel A, Gimm O, Weihe E, Knoefel WT, Dralle H, Heitz PU, Komminoth P, Kl\u00f6ppel G. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut. 2007;56(5):637\u201344. https:\/\/doi.org\/10.1136\/gut.2006.108910.","journal-title":"Gut"},{"key":"8354_CR70","doi-asserted-by":"publisher","unstructured":"Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M. (2018). Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability. JCO Precis Oncol. 2018. https:\/\/doi.org\/10.1200\/po.17.00267.","DOI":"10.1200\/po.17.00267"},{"issue":"6","key":"8354_CR71","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/pas.0000000000001860","volume":"46","author":"M Parilla","year":"2022","unstructured":"Parilla M, Chapel D, Hechtman JF, Wanjari P, El Jabbour T, Sharma A, Ritterhouse L, Segal J, Vanderbilt C, Klimstra DS, Setia N, Tang L. Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2022;46(6):823\u201331. https:\/\/doi.org\/10.1097\/pas.0000000000001860.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"8354_CR72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s42003-020-01469-0","volume":"4","author":"V Lakis","year":"2021","unstructured":"Lakis V, Lawlor RT, Newell F, Patch AM, Mafficini A, Sadanandam A, Koufariotis LT, Johnston RL, Leonard C, Wood S, Rusev B, Corbo V, Luchini C, Cingarlini S, Landoni L, Salvia R, Milella M, Chang D, Bailey P, Scarpa A. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Commun Biol. 2021;4(1):155. https:\/\/doi.org\/10.1038\/s42003-020-01469-0.","journal-title":"Commun Biol"},{"key":"8354_CR73","doi-asserted-by":"publisher","unstructured":"Qi Z, Tan H. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Biosci Rep. 2020;40(3). https:\/\/doi.org\/10.1042\/bsr20194127.","DOI":"10.1042\/bsr20194127"},{"issue":"8","key":"8354_CR74","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1530\/erc-16-0117","volume":"23","author":"J Cros","year":"2016","unstructured":"Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, L\u00e9vy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(8):625\u201333. https:\/\/doi.org\/10.1530\/erc-16-0117.","journal-title":"Endocr Relat Cancer"},{"key":"8354_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2024.11.020","author":"J Kim","year":"2024","unstructured":"Kim J, Hong SS, Kim SH, Hwang HK, Hong N, Rhee Y, Kang CM. Genotype-based prognosis prediction for MEN1-Related pancreatic neuroendocrine tumors in Korean patients a single-center retrospective study. Pancreatology. 2024. https:\/\/doi.org\/10.1016\/j.pan.2024.11.020.","journal-title":"Pancreatology"},{"issue":"1","key":"8354_CR76","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.surg.2017.04.044","volume":"163","author":"I Christakis","year":"2018","unstructured":"Christakis I, Qiu W, Hyde SM, Cote GJ, Grubbs EG, Perrier ND, Lee JE. Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. Surgery. 2018;163(1):212\u20137. https:\/\/doi.org\/10.1016\/j.surg.2017.04.044.","journal-title":"Surgery"},{"issue":"2","key":"8354_CR77","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.Ccr-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME, Bahary N, Brand RE, McGrath KM, Slivka A, Cressman KL, Fuhrer K, O\u2019Sullivan RJ. Alternative Lengthening of Telomeres and Loss of DAXX\/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2017;23(2):600\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1113.","journal-title":"Clin Cancer Res"},{"key":"8354_CR78","doi-asserted-by":"publisher","unstructured":"Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015;22(3):L13-8.. https:\/\/doi.org\/10.1530\/erc-15-0108.","DOI":"10.1530\/erc-15-0108"},{"issue":"5","key":"8354_CR79","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY, O\u2019Sullivan R, Sung YN, Liu TC, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink FHM, Heidsma CM, Valk GD, Vriens MR, van Nieveen E, Offerhaus GJA, Dreijerink KMA, Zeh H, Zureikat AH, Singhi AD. Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut. 2022;71(5):961\u201373. https:\/\/doi.org\/10.1136\/gutjnl-2020-322595.","journal-title":"Gut"},{"issue":"6","key":"8354_CR80","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.Ccr-16-1147","volume":"23","author":"JY Kim","year":"2017","unstructured":"Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017;23(6):1598\u2013606. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1147.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8354_CR81","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/sla.0000000000003022","volume":"271","author":"A Pea","year":"2020","unstructured":"Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Chianchiano P, Gobbo S, Regi P, Salvia R, Bassi C, He J, Weiss MJ, Cameron JL, Offerhaus GJA, Wolfgang CL. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. Ann Surg. 2020;271(3):566\u201373. https:\/\/doi.org\/10.1097\/sla.0000000000003022.","journal-title":"Ann Surg"},{"issue":"9","key":"8354_CR82","doi-asserted-by":"publisher","first-page":"957","DOI":"10.7150\/ijbs.9773","volume":"10","author":"F Yuan","year":"2014","unstructured":"Yuan F, Shi M, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J. KRAS and DAXX\/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors. Int J Biol Sci. 2014;10(9):957\u201365. https:\/\/doi.org\/10.7150\/ijbs.9773.","journal-title":"Int J Biol Sci"},{"key":"8354_CR83","doi-asserted-by":"publisher","first-page":"1351624","DOI":"10.3389\/fendo.2024.1351624","volume":"15","author":"K Andersen","year":"2024","unstructured":"Andersen K, Detlefsen S, Brusgaard K, Christesen HT. Well-differentiated G1 and G2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded DNA sequencing data. Front Endocrinol (Lausanne). 2024;15:1351624. https:\/\/doi.org\/10.3389\/fendo.2024.1351624.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"8354_CR84","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","volume":"146","author":"I Marinoni","year":"2014","unstructured":"Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, Hunger F, Pasquinelli S, Speel EJ, Perren A. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014;146(2):453\u201360. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.020. e5.","journal-title":"Gastroenterology"},{"issue":"8","key":"8354_CR85","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41591-019-0493-4","volume":"25","author":"P Cejas","year":"2019","unstructured":"Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Shivdasani RA. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med. 2019;25(8):1260\u20135. https:\/\/doi.org\/10.1038\/s41591-019-0493-4.","journal-title":"Nat Med"},{"issue":"11","key":"8354_CR86","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/j.modpat.2024.100595","volume":"37","author":"E Moser","year":"2024","unstructured":"Moser E, Ura A, Vogel L, Steiger K, Mogler C, Evert M, M\u00e4rkl B, Scheidhauer K, Martignoni M, Friess H, von Werder A, Marinoni I, Perren A, Kl\u00f6ppel G, Kasajima A. ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and Outcome. Mod Pathol. 2024;37(11):100595. https:\/\/doi.org\/10.1016\/j.modpat.2024.100595.","journal-title":"Mod Pathol"},{"issue":"1","key":"8354_CR87","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s42003-020-01479-y","volume":"3","author":"A Di Domenico","year":"2020","unstructured":"Di Domenico A, Pipinikas CP, Maire RS, Br\u00e4utigam K, Simillion C, Dettmer MS, Vassella E, Thirlwell C, Perren A, Marinoni I. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020;3(1):740. https:\/\/doi.org\/10.1038\/s42003-020-01479-y.","journal-title":"Commun Biol"},{"key":"8354_CR88","doi-asserted-by":"publisher","unstructured":"Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle, Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2):245\u2009\u2013\u200955. https:\/\/doi.org\/10.1200\/jco.2008.21.5988.","DOI":"10.1200\/jco.2008.21.5988"},{"issue":"5","key":"8354_CR89","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1007\/s13277-013-0849-1","volume":"34","author":"X Han","year":"2013","unstructured":"Han X, Ji Y, Zhao J, Xu X, Lou W. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumour Biol. 2013;34(5):2871\u20139. https:\/\/doi.org\/10.1007\/s13277-013-0849-1.","journal-title":"Tumour Biol"},{"key":"8354_CR90","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.cpccr.2020.100037","volume":"2","author":"R Park","year":"2020","unstructured":"Park R, Chatterjee D, Amin M, Trikalinos NA. Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor. Curr Probl Cancer: Case Rep. 2020;2:100037. https:\/\/doi.org\/10.1016\/j.cpccr.2020.100037.","journal-title":"Curr Probl Cancer: Case Rep"},{"issue":"2","key":"8354_CR91","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/jme-14-0304","volume":"54","author":"T Vandamme","year":"2015","unstructured":"Vandamme T, Peeters M, Dogan F, Pauwels P, Van Assche E, Beyens M, Mortier G, Vandeweyer G, de Herder W, Van Camp G, Hofland LJ, de Op K. Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. J Mol Endocrinol. 2015;54(2):137\u201347. https:\/\/doi.org\/10.1530\/jme-14-0304.","journal-title":"J Mol Endocrinol"},{"issue":"5","key":"8354_CR92","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/ana.21037","volume":"60","author":"AC Jansen","year":"2006","unstructured":"Jansen AC, Sancak O, D\u2019Agostino MD, Badhwar A, Roberts P, Gobbi G, Wilkinson R, Melanson D, Tampieri D, Koenekoop R, Gans M, Maat-Kievit A, Goedbloed M, van den Ouweland AMW, Nellist M, Pandolfo M, McQueen M, Sims K, Thiele EA, Andermann E. Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol. 2006;60(5):528\u201339. https:\/\/doi.org\/10.1002\/ana.21037.","journal-title":"Ann Neurol"},{"issue":"1","key":"8354_CR93","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12964-024-01545-6","volume":"22","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Dong YH, Zhao SW, Liu DY, Zhang JY, Xu XY, Chen H, Chen H, Jin JB. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns. Cell Commun Signal. 2024;22(1):164. https:\/\/doi.org\/10.1186\/s12964-024-01545-6.","journal-title":"Cell Commun Signal"},{"key":"8354_CR94","doi-asserted-by":"publisher","unstructured":"Gujarathi R, Abou Azar S, Tobias J, Polite BN, Setia N, Feinberg N, Appelbaum DE, Keutgen XM, Liao CY. MEN1\/DAXX\/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024;31(11). https:\/\/doi.org\/10.1530\/erc-24-0065.","DOI":"10.1530\/erc-24-0065"},{"issue":"1","key":"8354_CR95","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","volume":"9","author":"CS Chan","year":"2018","unstructured":"Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, Chan TA, Klimstra DS, Allis CD, Tang LH. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. 2018;9(1):4158. https:\/\/doi.org\/10.1038\/s41467-018-06498-2.","journal-title":"Nat Commun"},{"key":"8354_CR96","doi-asserted-by":"publisher","unstructured":"Hong X, Zhang X, Jiang R, Qiao S, Wang W, Zhang H, Wang J, Yin B, Li F, Ling C, Wang X, Zhao Y, Wu K, Wu W. A cross-species transcriptomic analysis reveals a novel 2-dimensional classification system explaining the invasiveness heterogeneity of pancreatic neuroendocrine tumor. Cancer Lett. 2024;217131. https:\/\/doi.org\/10.1016\/j.canlet.2024.217131.","DOI":"10.1016\/j.canlet.2024.217131"},{"issue":"6","key":"8354_CR97","doi-asserted-by":"publisher","first-page":"e949","DOI":"10.1097\/sla.0000000000003624","volume":"274","author":"J Uemura","year":"2021","unstructured":"Uemura J, Okano K, Oshima M, Suto H, Ando Y, Kumamoto K, Kadota K, Ichihara S, Kokudo Y, Maeba T, Nanno Y, Toyama H, Takada Y, Shimada M, Hanazaki K, Masaki T, Suzuki Y. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors. Ann Surg. 2021;274(6):e949\u201356. https:\/\/doi.org\/10.1097\/sla.0000000000003624.","journal-title":"Ann Surg"},{"issue":"1","key":"8354_CR98","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12022-025-09889-6","volume":"36","author":"S Avanthay","year":"2025","unstructured":"Avanthay S, Di Domenico A, Kirchner P, Br\u00e4utigam K, Chouchane A, Maire R, Thirlwell C, Kim-Fuchs C, Perren A, Marinoni I. Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1\/DAXX\/ATRX Explain Biological Variability. Endocr Pathol. 2025;36(1):44. https:\/\/doi.org\/10.1007\/s12022-025-09889-6.","journal-title":"Endocr Pathol"},{"issue":"1","key":"8354_CR99","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1038\/s41598-024-58874-2","volume":"14","author":"ME Fuentes","year":"2024","unstructured":"Fuentes ME, Lu X, Flores NM, Hausmann S, Mazur PK. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice. Sci Rep. 2024;14(1):8510. https:\/\/doi.org\/10.1038\/s41598-024-58874-2.","journal-title":"Sci Rep"},{"issue":"4","key":"8354_CR100","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/his.14996","volume":"83","author":"A Neyaz","year":"2023","unstructured":"Neyaz A, Crotty R, Rickelt S, Pankaj A, Stojanova M, Michelakos TP, Sekigami Y, Kontos F, Parrack PH, Patil DT, Heaphy CM, Ferrone CR, Deshpande V. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT). Histopathology. 2023;83(4):546\u201358. https:\/\/doi.org\/10.1111\/his.14996.","journal-title":"Histopathology"},{"issue":"2","key":"8354_CR101","doi-asserted-by":"publisher","first-page":"109817","DOI":"10.1016\/j.celrep.2021.109817","volume":"37","author":"KC Yang","year":"2021","unstructured":"Yang KC, Kalloger SE, Aird JJ, Lee MKC, Rushton C, Mungall KL, Mungall AJ, Gao D, Chow C, Xu J, Karasinska JM, Colborne S, Jones SJM, Schrader J, Morin RD, Loree JM, Marra MA, Renouf DJ, Morin GB, Gorski SM. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Rep. 2021;37(2):109817. https:\/\/doi.org\/10.1016\/j.celrep.2021.109817.","journal-title":"Cell Rep"},{"issue":"4","key":"8354_CR102","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2025.03.016","volume":"43","author":"S Ji","year":"2025","unstructured":"Ji S, Cao L, Gao J, Du Y, Ye Z, Lou X, Liu F, Zhang Y, Xu J, Shi X, Wang H, Li P, Li Y, Chen H, Yang Z, Gao S, Zhang W, Huang D, Ni S, Yu X. Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups. Cancer Cell. 2025;43(4):776\u2013e79614. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.016.","journal-title":"Cancer Cell"},{"issue":"2","key":"8354_CR103","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1210\/endrev\/bnac025","volume":"44","author":"RA Toledo","year":"2023","unstructured":"Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PLM. Hypoxia-Inducible Factor 2 Alpha (HIF2\u03b1) Inhibitors: Targeting Genetically Driven Tumor Hypoxia. Endocr Rev. 2023;44(2):312\u201322. https:\/\/doi.org\/10.1210\/endrev\/bnac025.","journal-title":"Endocr Rev"},{"issue":"8","key":"8354_CR104","doi-asserted-by":"publisher","first-page":"110544","DOI":"10.1016\/j.isci.2024.110544","volume":"27","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Ogawa M, Zhou Y, Otani Y, Hendrickson RC, Miele MM, Li Z, Klimstra DS, Wang JY, Roehrl MH. Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes. iScience. 2024;27(8):110544. https:\/\/doi.org\/10.1016\/j.isci.2024.110544.","journal-title":"iScience"},{"issue":"5","key":"8354_CR105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11604-017-0627-x","volume":"35","author":"F Toshima","year":"2017","unstructured":"Toshima F, Inoue D, Komori T, Yoshida K, Yoneda N, Minami T, Matsui O, Ikeda H, Gabata T. Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors? Jpn J Radiol. 2017;35(5):242\u201353. https:\/\/doi.org\/10.1007\/s11604-017-0627-x.","journal-title":"Jpn J Radiol"},{"issue":"2","key":"8354_CR106","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/mpa.0000000000000443","volume":"45","author":"S Yamada","year":"2016","unstructured":"Yamada S, Fujii T, Suzuki K, Inokawa Y, Kanda M, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Nakao A, Kodera Y. Preoperative Identification of a Prognostic Factor for Pancreatic Neuroendocrine Tumors Using Multiphase Contrast-Enhanced Computed Tomography. Pancreas. 2016;45(2):198\u2013203. https:\/\/doi.org\/10.1097\/mpa.0000000000000443.","journal-title":"Pancreas"},{"issue":"1","key":"8354_CR107","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.diii.2024.08.003","volume":"106","author":"F Lopez-Ramirez","year":"2025","unstructured":"Lopez-Ramirez F, Soleimani S, Azadi JR, Sheth S, Kawamoto S, Javed AA, Tixier F, Hruban RH, Fishman EK, Chu LC. Radiomics machine learning algorithm facilitates detection of small pancreatic neuroendocrine tumors on CT. Diagn Interv Imaging. 2025;106(1):28\u201340. https:\/\/doi.org\/10.1016\/j.diii.2024.08.003.","journal-title":"Diagn Interv Imaging"},{"issue":"4","key":"8354_CR108","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2214\/ajr.19.22123","volume":"215","author":"Y Bian","year":"2020","unstructured":"Bian Y, Jiang H, Ma C, Wang L, Zheng J, Jin G, Lu J. CT-Based Radiomics Score for Distinguishing Between Grade 1 and Grade 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol. 2020;215(4):852\u201363. https:\/\/doi.org\/10.2214\/ajr.19.22123.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"8354_CR109","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1186\/s12967-024-05449-4","volume":"22","author":"M Ma","year":"2024","unstructured":"Ma M, Gu W, Liang Y, Han X, Zhang M, Xu M, Gao H, Tang W, Huang D. A novel model for predicting postoperative liver metastasis in R0 resected pancreatic neuroendocrine tumors: integrating computational pathology and deep learning-radiomics. J Transl Med. 2024;22(1):768. https:\/\/doi.org\/10.1186\/s12967-024-05449-4.","journal-title":"J Transl Med"},{"key":"8354_CR110","doi-asserted-by":"publisher","first-page":"102269","DOI":"10.1016\/j.eclinm.2023.102269","volume":"65","author":"W Gu","year":"2023","unstructured":"Gu W, Chen Y, Zhu H, Chen H, Yang Z, Mo S, Zhao H, Chen L, Nakajima T, Yu X, Ji S, Gu Y, Chen J, Tang W. Development and validation of CT-based radiomics deep learning signatures to predict lymph node metastasis in non-functional pancreatic neuroendocrine tumors: a multicohort study. EClinicalMedicine. 2023;65:102269. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102269.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"8354_CR111","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/meg.0000000000000332","volume":"27","author":"X Han","year":"2015","unstructured":"Han X, Zhang C, Tang M, Xu X, Liu L, Ji Y, Pan B, Lou W. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur J Gastroenterol Hepatol. 2015;27(5):527\u201335. https:\/\/doi.org\/10.1097\/meg.0000000000000332.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"8354_CR112","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.hpb.2018.09.016","volume":"21","author":"A Pulvirenti","year":"2019","unstructured":"Pulvirenti A, Rao D, McIntyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ. Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. HPB (Oxford). 2019;21(5):612\u20138. https:\/\/doi.org\/10.1016\/j.hpb.2018.09.016.","journal-title":"HPB (Oxford)"},{"issue":"3","key":"8354_CR113","doi-asserted-by":"publisher","first-page":"336","DOI":"10.17305\/bjbms.2020.4632","volume":"20","author":"T Tomita","year":"2020","unstructured":"Tomita T. Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors. Bosn J Basic Med Sci. 2020;20(3):336\u201346. https:\/\/doi.org\/10.17305\/bjbms.2020.4632.","journal-title":"Bosn J Basic Med Sci"},{"issue":"4","key":"8354_CR114","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12022-020-09645-y","volume":"31","author":"CC Juhlin","year":"2020","unstructured":"Juhlin CC, Zedenius J, H\u00f6\u00f6g A. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin. Endocr Pathol. 2020;31(4):401\u201310. https:\/\/doi.org\/10.1007\/s12022-020-09645-y.","journal-title":"Endocr Pathol"},{"key":"8354_CR115","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.2147\/cmar.S250071","volume":"12","author":"X Chen","year":"2020","unstructured":"Chen X, Guo C, Cui W, Sun K, Wang Z, Chen X. CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms. Cancer Manag Res. 2020;12:4625\u201331. https:\/\/doi.org\/10.2147\/cmar.S250071.","journal-title":"Cancer Manag Res"},{"key":"8354_CR116","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jss.2016.12.033","volume":"211","author":"KA Mirkin","year":"2017","unstructured":"Mirkin KA, Hollenbeak CS, Wong J. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors\u2009\u2264\u20092\u00a0cm. J Surg Res. 2017;211:206\u201314. https:\/\/doi.org\/10.1016\/j.jss.2016.12.033.","journal-title":"J Surg Res"},{"issue":"4","key":"8354_CR117","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cncy.22242","volume":"128","author":"D Kim","year":"2020","unstructured":"Kim D, Viswanathan K, Goyal A, Rao R. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Cancer Cytopathol. 2020;128(4):269\u201377. https:\/\/doi.org\/10.1002\/cncy.22242.","journal-title":"Cancer Cytopathol"},{"issue":"5","key":"8354_CR118","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","volume":"440","author":"M Papotti","year":"2002","unstructured":"Papotti M, Bongiovanni M, Volante M, All\u00eca E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G. Expression of somatostatin receptor types 1\u20135 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440(5):461\u201375. https:\/\/doi.org\/10.1007\/s00428-002-0609-x.","journal-title":"Virchows Arch"},{"issue":"2","key":"8354_CR119","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12022-007-0014-8","volume":"18","author":"GM Portela-Gomes","year":"2007","unstructured":"Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4. Endocr Pathol. 2007;18(2):79\u201385. https:\/\/doi.org\/10.1007\/s12022-007-0014-8.","journal-title":"Endocr Pathol"},{"issue":"23","key":"8354_CR120","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1002\/cncr.28341","volume":"119","author":"K Okuwaki","year":"2013","unstructured":"Okuwaki K, Kida M, Mikami T, Yamauchi H, Imaizumi H, Miyazawa S, Iwai T, Takezawa M, Saegusa M, Watanabe M, Koizumi W. Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes. Cancer. 2013;119(23):4094\u2013102. https:\/\/doi.org\/10.1002\/cncr.28341.","journal-title":"Cancer"},{"issue":"4","key":"8354_CR121","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3892\/etm.2021.10613","volume":"22","author":"O Popa","year":"2021","unstructured":"Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med. 2021;22(4):1179. https:\/\/doi.org\/10.3892\/etm.2021.10613.","journal-title":"Exp Ther Med"},{"issue":"1","key":"8354_CR122","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1385\/mo:20:1:59","volume":"20","author":"ML Fj\u00e4llskog","year":"2003","unstructured":"Fj\u00e4llskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol. 2003;20(1):59\u201367. https:\/\/doi.org\/10.1385\/mo:20:1:59.","journal-title":"Med Oncol"},{"key":"8354_CR123","doi-asserted-by":"publisher","unstructured":"Gomes-Porras M, C\u00e1rdenas-Salas J, \u00c1lvarez-Escol\u00e1 C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020;21(5). https:\/\/doi.org\/10.3390\/ijms21051682.","DOI":"10.3390\/ijms21051682"},{"issue":"2","key":"8354_CR124","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12020-017-1482-3","volume":"59","author":"AD Herrera-Mart\u00ednez","year":"2018","unstructured":"Herrera-Mart\u00ednez AD, Gahete MD, Pedraza-Arevalo S, S\u00e1nchez-S\u00e1nchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, G\u00e1lvez-Moreno MA, Casta\u00f1o JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine. 2018;59(2):426\u201337. https:\/\/doi.org\/10.1007\/s12020-017-1482-3.","journal-title":"Endocrine"},{"issue":"3","key":"8354_CR125","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/1878-0261.13107","volume":"16","author":"S Pedraza-Arevalo","year":"2022","unstructured":"Pedraza-Arevalo S, Ib\u00e1\u00f1ez-Costa A, Bl\u00e1zquez-Encinas R, Branco MR, V\u00e1zquez-Borrego MC, Herrera-Mart\u00ednez AD, Venegas-Moreno E, Serrano-Blanch R, Arjona-S\u00e1nchez \u00c1, G\u00e1lvez-Moreno MA, Korbonits M, Soto-Moreno A, Gahete MD, Charalambous M, Luque RM, Casta\u00f1o JP. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors. Mol Oncol. 2022;16(3):764\u201379. https:\/\/doi.org\/10.1002\/1878-0261.13107.","journal-title":"Mol Oncol"},{"key":"8354_CR126","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/tcrm.S361332","volume":"18","author":"B Molasy","year":"2022","unstructured":"Molasy B, Zem\u0142a P, Mrowiec S, Grudzi\u0144ska E, Ku\u015bnierz K. Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors. Ther Clin Risk Manag. 2022;18:745\u201352. https:\/\/doi.org\/10.2147\/tcrm.S361332.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"8354_CR127","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.surg.2022.08.020","volume":"172","author":"A Nie\u00dfen","year":"2022","unstructured":"Nie\u00dfen A, Schimmack S, Lewosinska M, Hinz U, Bechtiger FA, Hackert T, B\u00fcchler MW, Strobel O. Lymph node metastases and recurrence in pancreatic neuroendocrine neoplasms. Surgery. 2022;172(6):1791\u20139. https:\/\/doi.org\/10.1016\/j.surg.2022.08.020.","journal-title":"Surgery"},{"issue":"4","key":"8354_CR128","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00535-021-01777-0","volume":"56","author":"WQ Wang","year":"2021","unstructured":"Wang WQ, Zhang WH, Gao HL, Huang D, Xu HX, Li S, Li TJ, Xu SS, Li H, Long J, Ye LY, Wu CT, Han X, Wang XH, Liu L, Yu XJ. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. J Gastroenterol. 2021;56(4):395\u2013405. https:\/\/doi.org\/10.1007\/s00535-021-01777-0.","journal-title":"J Gastroenterol"},{"issue":"4","key":"8354_CR129","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1245\/s10434-016-5663-8","volume":"24","author":"Y Nanno","year":"2017","unstructured":"Nanno Y, Matsumoto I, Zen Y, Otani K, Uemura J, Toyama H, Asari S, Goto T, Ajiki T, Okano K, Suzuki Y, Takeyama Y, Fukumoto T, Ku Y. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. Ann Surg Oncol. 2017;24(4):1127\u201333. https:\/\/doi.org\/10.1245\/s10434-016-5663-8.","journal-title":"Ann Surg Oncol"},{"key":"8354_CR130","doi-asserted-by":"publisher","unstructured":"Ney A, Canciani G, Hsuan JJ, Pereira SP. Modelling pancreatic neuroendocrine cancer: from bench side to clinic. Cancers (Basel). 2020;12(11). https:\/\/doi.org\/10.3390\/cancers12113170.","DOI":"10.3390\/cancers12113170"},{"key":"8354_CR131","doi-asserted-by":"publisher","unstructured":"Zhang T, Xiang Y, Wang H, Yun H, Liu Y, Wang X, Zhang H. Radiomics combined with multiple machine learning algorithms in differentiating pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumor: more hands produce a stronger flame. J Clin Med. 2022;11(22). https:\/\/doi.org\/10.3390\/jcm11226789.","DOI":"10.3390\/jcm11226789"},{"key":"8354_CR132","doi-asserted-by":"publisher","unstructured":"Hasic Telalovic J, Pillozzi S, Fabbri R, Laffi A, Lavacchi D, Rossi V, Dreoni L, Spada F, Fazio N, Amedei A, Iadanza E, Antonuzzo L. A Machine learning decision support system (DSS) for neuroendocrine tumor patients treated with somatostatin analog (SSA) therapy. Diagnostics (Basel). 2021;11(5). https:\/\/doi.org\/10.3390\/diagnostics11050804.","DOI":"10.3390\/diagnostics11050804"},{"key":"8354_CR133","doi-asserted-by":"publisher","first-page":"110072","DOI":"10.1016\/j.radonc.2023.110072","volume":"191","author":"S Cilla","year":"2024","unstructured":"Cilla S, Campitelli M, Antonietta Gambacorta M, Michela Rinaldi R, Deodato F, Pezzulla D, Romano C, Fodor A, Laliscia C, Trippa F, De Sanctis V, Ippolito E, Ferioli M, Titone F, Russo D, Balcet V, Vicenzi L, Di Cataldo V, Raguso A, Macchia G. Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study. Radiother Oncol. 2024;191:110072. https:\/\/doi.org\/10.1016\/j.radonc.2023.110072.","journal-title":"Radiother Oncol"},{"key":"8354_CR134","doi-asserted-by":"publisher","unstructured":"Xia F, Chen Q, Liu Z, Zhang Q, Guo B, Fan F, Huang Z, Zheng J, Gao H, Xia G, Ren L, Mei H, Chen X, Cheng Q, Zhang B, Zhu P. Machine learning models for predicting postoperative peritoneal metastasis after hepatocellular carcinoma rupture: a multicenter cohort study in China. Oncologist. 2025;30(1). https:\/\/doi.org\/10.1093\/oncolo\/oyae341.","DOI":"10.1093\/oncolo\/oyae341"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08354-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08354-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08354-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:03:21Z","timestamp":1785798201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08354-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":134,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8354"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08354-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"981"}}